Arrowhead Pharmaceuticals, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) develops RNA interference (RNAi) therapeutics that silence genes causing intractable diseases using its proprietary Targeted RNAi Molecule (TRiM™) platform; the company's pipeline includes approximately 20 investigational medicines in clinical development across cardiometabolic, pulmonary, liver, neuromuscular, central nervous system, and complement-mediated disease areas, featuring lead candidates such as plozasiran (ARO-APOC3) for severe hypertriglyceridemia and familial chylomicronemia syndrome, zodasiran (ARO-ANG3) for mixed dyslipidemia and homozygous familial hypercholesterolemia, fazirsiran (ARO-AAT) for alpha-1 antitrypsin deficiency-associated liver disease, ARO-C3 for complement-mediated diseases like IgA nephropathy, ARO-MUC5AC and ARO-RAGE for muco-obstructive and inflammatory lung diseases, ARO-HBV for hepatitis B, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and others targeting conditions including chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and metabolic dysfunction-associated steatohepatitis. Founded in 2003 and headquartered in Pasadena, California, with research and development facilities in Madison and Verona, Wisconsin, and San Diego, California, Arrowhead operates primarily in the United States while advancing partnered and wholly owned programs globally through collaborations with major pharmaceutical companies. Recent developments include a November 2024 global license and collaboration agreement with Sarepta Therapeutics covering multiple clinical and preclinical programs in rare genetic diseases of muscle, CNS, and lungs, providing Arrowhead with $500 million upfront cash, $325 million in equity investment, and potential milestones exceeding $2.7 billion, alongside a $200 million milestone payment from Sarepta in 2025 for progress in the Phase 1/2 study of ARO-DM1 (SRP-1003) for type 1 myotonic dystrophy; the company also maintains ongoing partnerships with GlaxoSmithKline, Takeda, Janssen, Amgen, Horizon Therapeutics, and others, reported FDA approval for its first product plozasiran (branded Redemplo) with a potential commercial launch in 2025 pending final review, and projects cash runway extension into 2028 supported by substantial collaboration revenue of $240.6 million for fiscal year 2024.
Company News
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Benjamin Edwards Inc. Makes New $721,000 Investment in Arrowhead Pharmaceuticals, Inc. $ARWR
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript
Arrowhead's Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
Deutsche Bank AG Invests $12.16 Million in Arrowhead Pharmaceuticals, Inc. $ARWR
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
California State Teachers Retirement System Has $9.05 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Purchased by Affinity Asset Advisors LLC
California Public Employees Retirement System Makes New Investment in Arrowhead Pharmaceuticals, Inc. $ARWR
Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat